Taysha Gene Therapies (NASDAQ:TSHA) CFO Kamran Alam Sells 78,968 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 78,968 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer directly owned 1,467,635 shares of the company’s stock, valued at approximately $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kamran Alam also recently made the following trade(s):

• On Monday, January 26th, Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89.

Taysha Gene Therapies Stock Up 0.8%

NASDAQ:TSHA opened at $4.76 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -14.42 and a beta of 1.02. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $6.02. The stock has a 50-day simple moving average of $5.09 and a 200 day simple moving average of $4.08.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on TSHA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, October 17th. Wells Fargo & Company increased their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Robert W. Baird lifted their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Finally, UBS Group set a $11.00 target price on Taysha Gene Therapies in a report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

More Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Institutional Trading of Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in TSHA. ST Germain D J Co. Inc. raised its stake in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies during the third quarter valued at $40,000. Marex Group plc bought a new stake in shares of Taysha Gene Therapies during the second quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the second quarter worth about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Taysha Gene Therapies by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock worth $73,000 after purchasing an additional 2,765 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.